Hyderabad, March 22: GV Research Platform (GVRP), a renowned provider of preclinical research services, has announced a partnership with Nexel, a leading specialist in induced pluripotent stem cell (iPSC) technology. Through this partnership, GVRP will become Nexel s authorized distribution partner in India for iPSC-derived cardiomyocytes, hepatocytes, and neurocytes. This partnership is a significant milestone for the biomedical community in India, as it will bring cutting-edge technology to the forefront of research and development. iPSC-derived cells have the potential to revolutionize drug discovery, toxicity testing, disease modeling, and regenerative medicine. These cells are an essential tool for drug development, as they provide a more physiologically relevant model for testing the efficacy and safety of new compounds. Dr. Choongseong Han, Founder and CEO of Nexel, expressed his pleasure in partnering with GVRP, saying, The collaboration will expand the reach of our cutting-edg
South Korea to host multi-stakeholder forum, discussing challenges and visions to promote alternatives to animal testing hsi.org - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from hsi.org Daily Mail and Mail on Sunday newspapers.